Stock Market Watch

Peregrine Pharmaceuticals – MLV Capital on Bavi program

by ·



Peregrine Pharmaceuticals (NASDAQ:PPHM). Last Market Price: 1.11, Change: -0.02, % Change: (-1.77%). Shares trade in the range of 1.11 – 1.14 dollars. It has a market capitalization of 88.29M dollars, making it a Small Cap Stock and has 79.54M outstanding shares. The company has a beta of 0.92, indicating, the stock to be less volatile than the market. As per the most recent quarterly report, the net income per share (EPS) is -0.53. It operates in Healthcare sector and belongs to Biotechnology and Drugs industry. Percentage shares held by institutional investors is 13%. The company has a 52 week high of $ 3.10 and a 52 week low of $ 0.95. Average volumes of shares traded daily are 507,926. Volume traded in the last session was at 25,089, 0.05 times the average volume.

  • MLV Capital is bullish on the company’s Bavi program
  • Is hopeful that the first randomized Phase II trials of Bavi will be positive
  • The firm holds the BUY on the stock
  • MLV Capital has set the target price of $8.50

For Q3 (Jul ’11), It had a Net profit margin of -143.09%, an Operating margin of -142.37%. Other Key stats and ratios are : Return on average assets of -105.07%, Return on average equity of -238.52%. The organization has an employee strength of 154

Consensus Recommendation is a Outperform.


Estimate for sales for the Quarter Ending Oct-11 show a mean of 2.16 million dollars, an estimate high of 2.20 million dollars and an estimate low of 2.08 million dollars.

Estimate for sales for the Quarter Ending Jan-12 show a mean of 2.15 million dollars, an estimate high of 2.30 million dollars and an estimate low of 1.88 million dollars.

Estimate for EPS for the Quarter Ending Oct-11 show a mean of -0.14 dollars, an estimate high of -0.13 dollars and an estimate low of -0.15 dollars.

Estimate for EPS for the Quarter Ending Jan-12 show a mean of -0.14 dollars, an estimate high of -0.12 dollars and an estimate low of -0.16 dollars.

Sales for Quarter Ending Jul-11 was estimated at 2.17 million dollars, however the actual sales figure stood at 5.66 million dollars, 3.48 million dollars more than estimates.

Sales for Quarter Ending Apr-11 was estimated at 2.28 million dollars, however the actual sales figure stood at 2.73 million dollars, 0.45 million dollars more than estimates.

edliston
Post Written By: Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing in his yacht.


Tags:

Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...